GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Interest Coverage

Vivos (RDGL) Interest Coverage : No Debt (1) (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Vivos Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Vivos's Operating Income for the three months ended in Dec. 2023 was $-0.94 Mil. Vivos's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Vivos has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Vivos Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Vivos's Interest Coverage or its related term are showing as below:

RDGL' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


RDGL's Interest Coverage is ranked better than
99.53% of 422 companies
in the Medical Devices & Instruments industry
Industry Median: 18.745 vs RDGL: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Vivos Interest Coverage Historical Data

The historical data trend for Vivos's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vivos Interest Coverage Chart

Vivos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - No Debt No Debt

Vivos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of Vivos's Interest Coverage

For the Medical Devices subindustry, Vivos's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Vivos's Interest Coverage falls into.



Vivos Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vivos's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Vivos's Interest Expense was $0.00 Mil. Its Operating Income was $-2.79 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Vivos had no debt (1).

Vivos's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Vivos's Interest Expense was $0.00 Mil. Its Operating Income was $-0.94 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Vivos had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Vivos  (OTCPK:RDGL) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Vivos Interest Coverage Related Terms

Thank you for viewing the detailed overview of Vivos's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos (RDGL) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadwin Avenue, Richland, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336

Vivos (RDGL) Headlines

From GuruFocus

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-11-2022

Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy

By Stock market mentor Stock market mentor 01-11-2023

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 05-12-2022

Vivos Inc. Provides Intellectual Property Protection Update

By PurpleRose PurpleRose 07-11-2022

Vivos Inc Implements Multiple Patient IsoPet� Therapy Day

By GuruFocusNews GuruFocusNews 04-21-2022

Vivos Inc Obtains Trademark Protection for IsoPet®

By Marketwired Marketwired 07-30-2018

Vivos Inc Initiates Isopet� Therapy in Horses

By Marketwired Marketwired 06-24-2021